Hebei Changshan Biochemical Pharmaceutical (300255.SZ): The clinical trial application for Abbinaide peptide injection for weight loss indication has been approved.
Changshan Pharmaceutical (300255.SZ) announced that the company and its holding subsidiary Changshan Kaijie Health Biopharmaceutical Research and Development (Hebei)...
Hebei Changshan Biochemical Pharmaceutical (300255.SZ) announced that the company and its holding subsidiary, Changshan Kaijie Jian Biological Pharmaceutical Research and Development (Hebei) Co., Ltd. (referred to as "Changshan Kaijie Jian"), recently received the Drug Clinical Trial Approval Letter issued by the National Medical Products Administration (NMPA). The joint application for clinical trials of Buepronatide injection for weight loss indication has been approved.
Related Articles
TRAD CHI MED (00570) proposes appointing PwC as the auditor.
Maison Group (01825): Zhou Runzhang resigns as independent non-executive director.
TRAD CHI MED(00570): Xu Jinghui transferred to the Nomination Committee as a member
TRAD CHI MED (00570) proposes appointing PwC as the auditor.
Maison Group (01825): Zhou Runzhang resigns as independent non-executive director.
TRAD CHI MED(00570): Xu Jinghui transferred to the Nomination Committee as a member
RECOMMEND
XPeng Motors Faces Whistleblower Allegations Over Steering Design Flaw and Concealment
20/06/2025
After Foundation Models, Intelligent Agents Take Center Stage as Tech Firms Accelerate Deployment | Live from MWC Shanghai
20/06/2025
Ministry of Commerce: Online Retail Sales Increased by 8.5% from January to May
20/06/2025
